English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/184040
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Effect of oral VCE-004.8, a cannabidiol quinol derivative, on experimental autoimmune encephalomyelitis

AuthorsNavarrete, Carmen; García, Adela; Palomares, Belén; Mestre, Leyre ; Mecha, Miriam ; Feliú, Ana; Garrido, Martín; Calzado, Marco A.; Bellido, María Luz ; Guaza, Carmen ; Muñoz, Eduardo
Issue Date2018
PublisherInternational Cannabinoid Research Society
Citation28th Annual Symposium of the International Cannabinoid Research Society: 22 (2018)
AbstractMultiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes that are dominantin different stages of the disease. Thus, immunosuppression is the goldstandard for the inflammatory stage and novel remyelination therapies are being pursued to restore lost function. While angiogenesis andblood-brain barrier(BBB)disruption are potentially negative in inflammatory phases, angiogenesis mediated by the stabilization of HIF-1αcould be beneficial for neuroprotection and axonal regeneration in remitting phases and progressive forms of the disease. Therefore, the development of complementary treatments aimed at axonal repair and remyelination and/or slowing the progression of the disease through neuroprotectionand axonal regeneration remain the most important objective in the clinical management of chronic progressive MS.
DescriptionTrabajo presentado en el 28th Annual Symposium of the International Cannabinoid Research Society, celebrado en Leiden del 30 de junio al 5 de julio de 2018.
Appears in Collections:(IC) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.